The Boston R&D campus, located in Waltham, is a strategic center for oncology and infectious disease research within the heart of the Boston life sciences ecosystem. It focuses on small-molecule oncology, infection innovative medicines, and advanced therapies for cancer and other serious diseases. The site fosters a collaborative environment for discovering novel agents and supports AstraZeneca's global R&D strategy in tumor immunology, precision medicine, and beyond.
The Frederick campus is AstraZeneca's largest drug substance biologics manufacturing center in the US, specializing in large-scale production of biologics for cancer, autoimmune, respiratory, and rare disease treatments. It employs cutting-edge mammalian cell culture technology to produce life-changing medicines, with ongoing expansions to double capacity and support commercial manufacturing needs.
The Gaithersburg campus serves as one of AstraZeneca's key strategic R&D centers in the US, focusing on pioneering biopharmaceutical innovations. It specializes in advancing science across oncology, respiratory and immunology, cardiovascular, renal & metabolism, and rare diseases. Home to over 4,500 experts, the campus emphasizes target biology, protein engineering, translational science, personalised healthcare, biopharmaceutical development, and clinical development. This vibrant scientific hub drives the discovery and development of life-changing medicines through cutting-edge research and collaboration.
The Wilmington campus functions as AstraZeneca's US commercial headquarters and business center, overseeing key operations in marketing, sales, and commercialization of biopharmaceutical products. It supports clinical research, market access, and corporate functions essential for delivering medicines to patients across the United States. As a hub for enabling functions, it integrates scientific advancements into practical healthcare solutions, focusing on oncology, biopharmaceuticals, and rare diseases.
